Taltz

RSS

ixekizumab

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Taltz. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Taltz.

For practical information about using Taltz, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 03/08/2018

Authorisation details

Product details
Name
Taltz
Agency product number
EMEA/H/C/003943
Active substance
ixekizumab
International non-proprietary name (INN) or common name
ixekizumab
Therapeutic area (MeSH)
Psoriasis
Anatomical therapeutic chemical (ATC) code
L04AC
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
25/04/2016
Contact address
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands

Product information

30/07/2018 Taltz - EMEA/H/C/003943 - N/0023

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Plaque psoriasis

Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Psoriatic arthritis

Taltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
2 ratings